ASCO 2016

Area: Oncology

Location: Chicago, United States

Date: June 3 to June 7

Description:

ASCO Annual Meeting.


Search in Scientific Content:
Date
Filters:
Metastatic
15:35

Metastatic urothelial carcinoma PD-L1 expression, Cancer Genome Atlas subtype, and mutational load as independent predictors of response to atezolizumab

Presenter: Jonathan E. Rosenberg
Oncology
Clinical t
9:52

Clinical trials - lung cancer, head and neck cancers - new ways, further developments of treatment, combinations

Presenter: Gregory A. Masters
Oncology
ASCO/ECCO
5:24

ASCO/ECCO Joint session: Value Based Care

Presenter: Peter Naredi
Oncology
CheckMate-
7:51

CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab alone or with ipilimumab in advanced and metastatic gastric cancer

Presenter: Yelena Janjigian
Oncology
US: Progre
5:40

US: Progress in Myeloproliferative Neoplasms

Presenter: Ruben A. Mesa
Oncology
Long-term
8:27

Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab

Presenter: Rina Hui
Oncology
Management
5:46

Management of Acute Lymphoblastic Leukemia

Presenter: Elias Jabbour
Oncology
Safety and
5:55

Safety and antitumor activity of hypofractionated stereotactic irradiation with pembrolizumab and bevacizumab in patients with recurrent high grade gliomas: Preliminary result

Presenter: Solmaz Sahebjam
Oncology
Advances i
5:23

Advances in the treatment of head and neck cancers - combination: radiation and immunotherapy

Presenter: Gregory A. Masters
Oncology
Breast Can
11:38

Breast Cancer-Triple Negative/Cytotoxics/Local Therapy - Breast cancer highlights of ASCO 2016

Presenter: Harold J. Burstein
Oncology
Novel agen
3:41

Novel agents in Non-Hodgkin Lymphoma, in CNS involvment, in Limited-Stage Hodgkin Lymphoma

Presenter: Laurie Helen Sehn
Oncology
Nivolumab ...
3:44

Nivolumab ± ipilimumab in treatment of patients with metastatic colorectal cancer with and without high microsatellite instability: CheckMate-142 interim results

Presenter: Michael Overman
Oncology
US: Trends
8:44

US: Trends, most important results at ASCO 2016 - Immunotherapy, checkpoint inhibitors, targeted therapies, brain tumor

Presenter: Alan Venook
Oncology

SABCS 2017

2017-12-05 - 2017-12-09
San Antonio, United States

ESMO 2017

2017-09-08 - 2017-09-12
Madrid, Spain

ICML 2017

2017-06-14 - 2017-06-17
Lugano, Switzerland

ASCO 2017

2017-06-02 - 2017-06-06
Chicago, United States

SABCS 2016

2016-12-06 - 2016-12-10
San Antonio, United States

ESMO 2016

2016-10-07 - 2016-10-11
Copenhagen, Denmark

ELCC 2016

2016-04-13 - 2016-04-16
Geneva, Switzerland

ESMO ECCO 2015

2015-09-25 - 2015-09-29
Vienna, Austria

ASCO 2015

2015-05-29 - 2015-06-02
Chicago, United States